The FDA's temporary enforcement pause covers six peptides, none approved. Doctors quoted say the evidence is thin, and one researcher disputes claims that BPC-157 is natural.
Recap by typeshit. Full story at BoxLife Magazine.
Experts debate how regulators should separate real patient customization from mass-produced copies, citing recent tirzepatide sterility recalls and impurity findings.
A legal walkthrough of the 503A rules behind the October 28 policy, the July advisory vote, and the HHS note that it may revisit the policy if safety signals appear.
The recall came after an FDA warning letter. The Regulatory Review uses it to dig into how compounded GLP-1s stayed on sale after shortages officially ended.
The peptide item sits among gene therapy, Neuralink and Medicare news. The Alliance for Safe Biologic Medicines has asked HHS to pause the policy, citing FDA scientists.
Oprah talks about how taking a GLP-1 changed the way she thinks about food noise. Tap through for her full comments.
The Washington meeting runs November 14 to 17, with primary REDEFINE 9 results and pediatric semaglutide research for kids 6 to under 12.
Loading…